HSPPC-90-C
Alternative Names: HSPPC 90CLatest Information Update: 06 Sep 2006
At a glance
- Originator Antigenics
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Jan 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 20 Apr 2000 Preclinical development for Cancer in USA (Unknown route)